Magnesium oxide
DrugMagnesium oxide 250 mg per day for children with weight < 15 kg, 500 mg per day for weight <15-30 kg, and 1000 mg per day for weight > 30 kg
Other names: MgO
NCT Number: NCT03054805
To compare the differences of fecal microflora between constipated and non-constipated healthy children, and evaluate the efficacy of probiotics in reducing symptoms of constipation and the influence of intestinal microflora in children with functional constipation.
Looking for future studies?
Notify Me6 month–10 year
All sexes
Interventional
Phase 4
The investigators performed a monocentric, prospective, randomized controlled trial including 120 pediatric patients (aged 6 months - 10 years old) with functional constipation and 30 healthy age-matched healthy children as control. The investigators shall evaluate the children according to the Rome III Diagnostic Criteria for functional constipation.
The 120 enrolled patients are randomized in to two groups: Group A receiving magnesium oxide and probiotics (MIYAIRI-BM), Group B receiving only magnesium oxide. Each patient is assigned the evaluation constipation symptoms and detection of microflora (beneficial and harmful bacteria) in fecal samples at the enrollment, 4 weeks, and 12 weeks. Patients who take less than 80% of the appropriate dose of medications are withdrawn from the study. All patients included in the study will be given informed oral consent before entering the study.
The data of the fecal microflora evaluated in 60 healthy children are used as control.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Rome III Diagnostic Criteria for functional constipation for children aged 6 months - 4 years old is as the following:
Rome III Diagnostic Criteria for functional constipation for children aged 4 years old and above is as the following:
Exclusion criteria
Magnesium oxide 250 mg per day for children with weight < 15 kg, 500 mg per day for weight <15-30 kg, and 1000 mg per day for weight > 30 kg
Other names: MgO
MIYAIRI-BM 1 g (1package) per day for children with weight < 15 kg, 2g per day for weight 15-30 kg, and 3g per day for weight > 30 kg
Other names: Clostridium Butyricum MIYAIRI
Time frame: Change from baseline Clostridium butyricum Miyairi expression at 3 months.
The expression of Clostridium butyricum Miyairi (CBM) in constipated children feces means a better outcome measure.
Chang Gung Memorial Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06196073
Functional Constipation
Denizli, Pamukkale, Turkey (Türkiye)
View Trial DetailsNCT06730594
Functional Constipation
Vadodara, Gujarat, India
View Trial DetailsNCT04166058
Functional Constipation, Irritable Bowel Syndrome With Constipation
Birmingham, Alabama, United States
View Trial DetailsNCT05760313
Functional Constipation
Phoenix, Arizona, United States
View Trial Details